Contrast dye study in ICU patients: what happens to kidney markers?
NCT ID NCT02881710
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at 50 intensive care patients to see how a contrast dye used in CT scans changes two kidney injury markers (TIMP-2 and IGFBP7) in urine. The goal was to understand if the dye causes a measurable increase in these markers. It was a small, observational study without a comparison group, so it helps gather knowledge rather than proving a treatment works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
contrast dye (iodinated contrast agent)
What this could lead to
If successful, this could help doctors better understand how contrast dye affects kidneys in critically ill patients, potentially leading to safer scanning practices.
What could go wrong
This is a small, early observational study with no control group, so results may not apply broadly. It only measures markers, not actual kidney outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EMERGENCY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU de Nantes
Nantes, 44093, France